Skip to main
VIR
VIR logo

Vir Biotechnology (VIR) Stock Forecast & Price Target

Vir Biotechnology (VIR) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 45%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

Vir Biotechnology Inc. demonstrates a robust pipeline with promising clinical results, particularly in its hepatitis B and HDV programs, which could lead to significant upside potential for the company's stock as near-term readouts are anticipated. The company has effectively established a framework for value-based pricing, highlighting the therapeutic potential and competitive advantage of its combination regimen, especially in the context of critical interventions for compensated cirrhotic patients. Additionally, Vir's commitment to disciplined financial execution and a focused strategy enhances its clinical momentum as it enters 2025, suggesting a strong outlook in the realms of infectious diseases and oncology.

Bears say

Vir Biotechnology has reported a decline in expected revenue, with collaboration revenue projected to decrease from $86 million in 2023 to $102 million, primarily due to reduced partnerships. Additionally, the company's overall revenue estimate has dropped from $580 million in 2023 to $531 million, influenced by portfolio restructuring and prioritization efforts. Furthermore, a significant workforce reduction of 30% and the risk of unmet clinical trial outcomes for its drug candidates underscore ongoing challenges that contribute to a negative outlook on the company's stock prospects.

Vir Biotechnology (VIR) has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 45% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vir Biotechnology and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vir Biotechnology (VIR) Forecast

Analysts have given Vir Biotechnology (VIR) a Buy based on their latest research and market trends.

According to 11 analysts, Vir Biotechnology (VIR) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vir Biotechnology (VIR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.